DTL
CBIO

Dynamic Technology Lab’s Crescent Biopharma CBIO Stock Holding History

Dynamic Technology Lab’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-112
Closed -$42K – 1118
2020
Q2 		$42K Buy
+112
New +$31.7K 0.01% 927
2020
Q1 		– Sell
-119
Closed -$63K – 1151
2019
Q4 		$63K Buy
+119
New +$64.4K 0.01% 909
2017
Q4 		– Sell
-190
Closed -$265K – 1120
2017
Q3 		$265K Buy
190
+58
+44% +$68.1K 0.04% 783
2017
Q2 		$146K Buy
+132
New +$109K 0.03% 916

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dynamic Technology Lab's CBIO Position: Q3 2020 in Review

Dynamic Technology Lab sold out of Crescent Biopharma (CBIO) in Q3 2020, closing a stake of 112 shares — an estimated $42K sold.

Dynamic Technology Lab first reported a position in CBIO in Q2 2017 and held it in 4 quarters. The position peaked at $265K in Q3 2017. 80 funds tracked by Wall St. Rank hold CBIO as of Q3 2020.

  • Dynamic Technology Lab reported no remaining Crescent Biopharma position as of Q3 2020 after selling out during the quarter.
  • Dynamic Technology Lab sold 112 Crescent Biopharma shares in Q3 2020, an estimated $42K.
  • Dynamic Technology Lab first reported a position in Crescent Biopharma in Q2 2017 and held it in 4 quarters.
  • Dynamic Technology Lab's Crescent Biopharma position peaked at $265K in Q3 2017.
  • 80 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2020.

Based on Dynamic Technology Lab's 13F filing for Q3 2020, filed 13 Nov 2020.